Aspire Biopharma faces potential Nasdaq delisting after compliance shortfall
Investing.com -- Bavarian Nordic (CSE:BAVA) on Friday said that a DKK 810 million gain from the sale of a priority review voucher will be booked in the third quarter of 2025, lifting its expected full-year EBITDA margin to 40-42%.
The biotech company said that its previous guidance for EBITDA margin before special items remains unchanged at 26-30%. The increase to 40-42% reflects the one-off income from the voucher sale.
First-half revenue rose 33% to nearly DKK 3 billion from DKK 2.26 billion in the same period last year. Second-quarter revenue increased to DKK 1.65 billion from DKK 1.43 billion a year earlier.
EBITDA margin before special items improved to 32% in the first half from 20% in the prior-year period. In the second quarter, the margin rose to 33% from 29% a year earlier.
Bavarian Nordic maintained its 2025 revenue guidance of DKK 6-6.60 billion.